Interest of Serum Periostin Dosage in Patients With Bone Fibrous Dysplasia

Not Applicable

Completed

• Conditions: Bone Fibrous Dysplasia

• Registration Number: NCT02868645
• Lead Sponsor: Hospices Civils de Lyon

Brief Summary

Fibrous dysplasia is a rare bone disease which can cause pain and fractures. It has been shown that periostin is over expressed in fibrous component in patients bones ; but periostin has never been measured out in serum of patients, although it is easy to assess. This study aims to show whether serum periostin is elevated in serum of patients with fibrous dysplasia, and if it is more elevated in patients with severe forms of the disease.

Detailed Description

Not available

Study Timeline

• Study Start: 2016-05-25
• Study First Submitted: 2016-08-11
• Study First Submitted QC: 2016-08-11
• Study First Posted: 2016-08-16
• Primary Completion: 2018-04-10
• Study Completion: 2018-04-10
• Status Verified: 2018-11
• Last Update Submitted: 2018-11-05
• Last Update Posted: 2018-11-07

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 65

Inclusion Criteria

• patients with fibrous dysplasia of the bone
• access to social security
• informed consent

Exclusion Criteria

• no informed consent
• pregnancy
• patients with a history of conditions known to increase periostin serum (stade IV cancer, severe asthma, pulmonary fibrosis...)

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Periostin rate in serum	At inclusion

Secondary Outcome Measures

Name	Time	Method
Periostin rate in serum in patients with Mac Cune Albright syndrome	At inclusion
Periostin rate in serum according to the number of fibrotic bones	At inclusion
Periostin rate in serum in patients with severe phenotype of the disease	At inclusion

Trial Locations

Locations (1)

Service de rhumatologie Pavillon F - Hôpital Edouard Herriot; 🇫🇷 Lyon cedex 03, France